Exclusive Summary

• This product, as an FDA-approved and launched generic Dactinomycin for Injection, possesses the quality compliance and market access advantages for international expansion, enabling rapid entry into global markets.
• Dactinomycin is a crucial therapeutic agent for various rare and pediatric cancers, with definite rigid market demand, and its original patent has expired for many years, leading to a relatively concentrated generic market.
• The drug holds a stable position in global guidelines, is listed as an Essential Medicine by the WHO, and has no suitable substitutes in specific tumor types, indicating high clinical value.
• Targeting niche markets, its US FDA-certified quality advantages and potential cost competitiveness can be leveraged for differentiated promotion in global pediatric oncology and rare disease channels.
• Seek overseas partners with sales experience in rare diseases and oncology, and established channels for pediatric products, to rapidly expand through a distribution model.